

101540084  
JC17 Rec'd PUSPTO 17 JUN 2005  
PATENT  
Customer No. 22,852  
Attorney Docket No. 08702.0098-01000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
COLLINS et al. ) Group Art Unit: Not Yet Assigned  
National Stage of International Application ) Examiner: Not Yet Assigned  
No.: PCT/IB2003/006304 Under 35 U.S.C. )  
371 )  
International Filing Date: December 22, 2003 ) Confirmation No.: Not Yet Assigned  
)  
For: ANTIBODIES AGAINST PD-1 AND  
USES THEREFOR

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed within three months of the date of entry of the national stage in an international application and before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Copies of the U.S. patent publications are not enclosed.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

10/540084 PATENT

Customer No. 22,852

Attorney Docket No. 08702.0098-01000

JCT17 REC'D IN CTO 17 JUN 2005

This submission does not represent that a search has been made or that no

better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: 6/17/05

By: Mary K. Ferguson  
Mary K. Ferguson  
Reg. No. 51,675

10/540084

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				National Stage of International Application No.: PCT/IB2003/006304 Under 35 U.S.C. 371 International Filing Date: December 22, 2003 First Named Inventor: Mary Collins et al. Art Unit: Not Yet Assigned Examiner Name: Not Yet Assigned Attorney Docket Number: 08702.0098-01000	
Sheet	1	of	1		

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-5,837,845	11/17/1998	Hirakawa et al.	
		US-2004-0213795-A1	10/28/2004	Collins et al.	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			
		WO 01/27272 A1	04/19/2001	Hamilton Brook et al.	
		WO 01/27279 A1	04/19/2004	Cambridge Antibody Technology	
		WO 02/078731 A1	10/10/2002	Wyeth	
		EP 0 945 464 A1	09/29/1999	Cambridge Antibody Technology	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			Translation <sup>6</sup>
		International Search Report, mailed May 18, 2004 for International Application No. PCT/IB2003/006304			
		Agata et al., "Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes," <i>International Immunology</i> 8:765-772 (1996)			
		Davies et al., "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding," <i>Immunotechnology</i> 2:169-179 (1996)			
		Vaughan et al., "Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library," <i>Nature Biotechnology</i> 14:309-314 (1996)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.